DR info

臨床試験数 : 14 / 薬物数 : 7 - (DrugBank : 1) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 5

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

NTBC
   National Center for Research Resources (NCRR)
      1994   Phase 2   NCT00004333   -
   University of Washington
      1998   -   NCT00004443   Canada;United States;
Nitisinone
   Cycle Pharmaceuticals Ltd.
      2015   Phase 1   NCT02750332   South Africa;
   Sutphin Drugs
      2019   -   NCT04113772   India;
   Swedish Orphan Biovitrum
      2014   Phase 3   NCT02323529   Belgium;Denmark;France;Germany;Sweden;
      2013   -   NCT02320084   Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Kosovo;Lithuania;Macedonia, The Former Yugoslav Republic of;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Spain;Sweden;Switzerland;United Kingdom;
      2012   Phase 1   NCT01734889   France;Germany;United Kingdom;
   Swedish Orphan Biovitrum AB
      2012   -   EUCTR2012-002286-36-DE   Germany;United Kingdom;
Nitisinone 10 mg Tablet High Compritol
   Cycle Pharmaceuticals Ltd.
      2015   Phase 1   NCT02750709   South Africa;
Nitisinone Baked Tablet
   Cycle Pharmaceuticals Ltd.
      2016   Phase 1   NCT02750345   South Africa;
Orfadin
   Cycle Pharmaceuticals Ltd.
      2016   Phase 1   NCT02750345   South Africa;
      2015   Phase 1   NCT02750709   South Africa;
   Sutphin Drugs
      2019   -   NCT04113772   India;
   Swedish Orphan Biovitrum AB (Publ)
      2014   Phase 4   EUCTR2013-004132-29-BE   Belgium;Denmark;Sweden;
      2014   -   EUCTR2013-004132-29-SE   Belgium;Denmark;Sweden;
      2014   -   EUCTR2013-004132-29-DK   Belgium;Denmark;Sweden;
Orfadin oral suspension 4mg/ml
   Swedish Orphan Biovitrum AB
      2012   -   EUCTR2012-002286-36-GB   Germany;United Kingdom;
      2012   -   EUCTR2012-002286-36-DE   Germany;United Kingdom;